One in Four Oral Semaglutide Users Discontinue Due to GI Side Effects: Database Analysis

Oral semaglutide had a significant discontinuation rate due to adverse effects, predominantly gastrointestinal, with patterns and predictors characterized in a large database analysis.

Ishiguro, Mizuki et al.·Diabetology international·2026·
RPEP-153562026RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

Oral semaglutide: significant AE-related discontinuation predominantly due to GI effects (nausea, vomiting, diarrhea), with patient risk factors identified for predicting discontinuation.

Key Numbers

How They Did This

Database analysis of oral semaglutide discontinuation patterns, reasons (AE types), and predictive factors.

Why This Research Matters

Oral GLP-1 drugs are the future of metabolic medicine, but GI tolerability limits adherence. Understanding discontinuation patterns enables better patient management.

The Bigger Picture

GI tolerability remains the Achilles heel of GLP-1 drugs, whether injectable or oral. Solving this would dramatically improve real-world effectiveness.

What This Study Doesn't Tell Us

Database study. Cannot capture patients who tolerated side effects. Self-selected population.

Questions This Raises

  • ?Could slower titration schedules reduce discontinuation?
  • ?Would anti-nausea co-medication improve oral semaglutide tolerability?
  • ?Are there genetic predictors of GI intolerance?

Trust & Context

Key Stat:
GI = main barrier Gastrointestinal side effects are the dominant reason patients stop oral semaglutide, with specific risk factors predicting who will discontinue
Evidence Grade:
Database analysis. Real-world tolerability data complementing clinical trial AE reporting.
Study Age:
Published in 2025.
Original Title:
Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes.
Published In:
Diabetology international, 17(1), 14 (2026)
Database ID:
RPEP-15356

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Do many people stop oral semaglutide due to side effects?

A significant proportion discontinue due to GI side effects — mainly nausea, vomiting, and diarrhea. Slow dose titration and taking the pill correctly can help minimize these effects.

How can I reduce nausea from oral semaglutide?

Take it on an empty stomach with a small sip of water, wait 30 minutes before eating, and ensure your doctor titrates the dose slowly. Some patients also benefit from anti-nausea strategies during the titration period.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-15356·https://rethinkpeptides.com/research/RPEP-15356

APA

Ishiguro, Mizuki; Nishimura, Rimei. (2026). Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes.. Diabetology international, 17(1), 14. https://doi.org/10.1007/s13340-025-00868-0

MLA

Ishiguro, Mizuki, et al. "Discontinuation of oral semaglutide due to adverse effects: a database study on Japanese individuals with type 2 diabetes.." Diabetology international, 2026. https://doi.org/10.1007/s13340-025-00868-0

RethinkPeptides

RethinkPeptides Research Database. "Discontinuation of oral semaglutide due to adverse effects: ..." RPEP-15356. Retrieved from https://rethinkpeptides.com/research/ishiguro-2026-discontinuation-of-oral-semaglutide

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.